Jove
Visualize
Contact Us

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of mitochondrial NADH:ubiquinone oxidoreductase by spinning oscillating magnetic fields causes toxicity in cancer cells.

FEBS letters·2026
Same author

A battery of assays for chasing ricin and its activity.

Toxicology letters·2025
Same author

Recombinant YopE and LcrV vaccine candidates protect mice against plague and yersiniosis.

Heliyon·2024
Same author

Development and validation of streptavidin-biotin-based double antibody sandwich ELISA for ricin diagnosis.

International immunopharmacology·2024
Same author

Identification of 2,4-Diaminoquinazoline Derivative as a Potential Small-Molecule Inhibitor against Chikungunya and Ross River Viruses.

Viruses·2023
Same author

Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells.

Scientific reports·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 30, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

RAS: target for cancer therapy.

Nandita Saxena1, Sitanshu Sekhar Lahiri, Shashank Hambarde

  • 1Department of Radiation Biology and Radioprotectors, Institute of Nuclear Medicine and Allied Sciences, Delhi, India.

Cancer Investigation
|September 18, 2008
PubMed
Summary

RAS proteins are crucial for cell growth and cancer development. Targeting RAS through various inhibitors shows promise as an effective anticancer therapy, with several agents progressing in clinical trials.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Jun 30, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • RAS proteins are key regulators of cell signaling pathways involved in cell growth, proliferation, and differentiation.
  • Aberrant RAS signaling, often due to activating mutations found in ~30% of human cancers, drives malignant transformation and tumor maintenance.
  • RAS proteins are therefore considered a critical target for novel anticancer therapies.

Purpose of the Study:

  • To review the current therapeutic strategies targeting RAS proteins for cancer treatment.
  • To discuss the different classes of anti-RAS agents currently under clinical evaluation.
  • To highlight the potential and future directions for RAS-targeted anticancer drug development.

Main Methods:

  • Review of existing literature on RAS signaling and targeted therapies.
  • Analysis of pharmacologic inhibitors targeting different aspects of RAS pathway.
  • Evaluation of clinical trial data for anti-RAS agents.

Main Results:

  • Activating RAS mutations are prevalent in human cancers, underscoring RAS as a viable therapeutic target.
  • Multiple anti-RAS strategies are in clinical development, including inhibitors of membrane association, downstream signaling, upstream pathways, and RAS expression.
  • Several novel therapeutic agents targeting RAS are demonstrating promising clinical outcomes.

Conclusions:

  • Targeting RAS represents a significant and evolving strategy in cancer therapy.
  • The diverse range of anti-RAS agents offers multiple avenues for intervention in various cancer types.
  • Continued research and clinical evaluation of these agents hold substantial hope for improved cancer treatment outcomes.